Top 10 drugdiscoverynews.com Competitors

bmjmedicine.bmj.com

Objective To compare routine high risk human papillomavirus (hrHPV) screening with cytological screening in two screening rounds in a well established, routine screening programme for cervical cancer.Design Population based cohort study.Setting Finland’s Mass Screening Registry, 2012-22, with diagnostic follow-up examinations until October 2024.Participants 1 180 491 women participating at least once in cytological test (PAP smear) or hrHPV based cervical cancer screening between 2012 and 2022.Main outcome measures Numbers and proportions of attendees, positive routine test results, follow-up screening referrals, colposcopy referrals, and incidence of cervical intraepithelial neoplasia ≥grade 2 (CIN2+) in the first and second hrHPV and cytological screening rounds. Results adjusted for age, year, region, and education.Results Data for 1 574 688 full screening rounds were analysed. The overall referral rate for colposcopy was 3.37% (n=12 273) in the hrHPV group and 0.98% (n=11 895) in the cytology group, with an adjusted risk ratio of 2.97 (95% confidence interval (CI) 2.87 to 3.07). The overall rate for detection of CIN2+ was 0.92% in the hrHPV group and 0.35% in the cytology group, with an adjusted risk ratio of 2.17 (2.04 to 2.31). For the second hrHPV screening round compared with the first screening round, the adjusted risk ratio was 0.77 (0.71 to 0.84) for referral for colposcopy and 0.57 (0.46 to 0.72) for detection of CIN2+. Actual rates for referral for colposcopy were 3.54% (n=11 709) in the first hrHPV screening round and 2.42% (n=564) in the second screening round. The rate for detection of CIN2+ for hrHPV screening was 0.98% (n=3 248) in the first hrHPV screening round and 0.38% (n=88) in the second screening round. In cytological screening, no observed reduction was seen in either the referral rate or CIN2+ findings. After a negative hrHPV test in the first screening round, CIN2+ was detected in only 0.2% of women (n=44/314 286) in the second screening

insmed.com

Partnerships Join our fearless fight Insmed is a global biopharmaceutical company that invests in scientific and commercial innovation to transform the lives of patients with serious and rare diseases. We have expertise in all stages of development, from concept to market, and industry-leading global commercial capabilities in the U.S., major EU markets, and Japan Insmed’s […]

askbio.com

Leading gene therapy company announces $235 million investment to accelerate growth

pacificcrestdermatology.com

Pacific Crest Dermatology is a woman-owned, physician-led clinic in Carson City, NV offering expert medical, surgical & cosmetic dermatology care.

kerecis.com

Kerecis Skin Substitute Questions and Answers. Learn more!

syncell.com

Advance your research with microscopy-guided tools for high-res protein discovery & mapping. See how our workflow enhances precision and discovery depth.

appliedpathology.com

CLIA-certified histopathology CRO offering general histology, IHC, RNAscope, spatial biology, image analysis, and clinical trial support. Fast turnaround. Based in Shrewsbury, MA. Request a quote today.

us.progen.com

The B1 antibody reacts with free VP1, VP2 and VP3 of adeno-associated virus (AAV) and at a reduced degree with assembled viral particles. VP1 and VP2 are highly enriched in the nucleus, while non-assembled VP3 is evenly distributed in the nucleus and the cytoplasm. Epitope mapping experiments (Wobus et al., 2000) identified aa726 to aa733 (C-terminus; common to all 3 VP proteins) as the specific binding region. The antibody is also useful for characterization of different stages of infection. Wobus, C. E. et al. Monoclonal antibodies against the adeno-associated virus type 2 (AAV-2) capsid: epitope mapping and identification of capsid domains involved in AAV-2-cell interaction and neutralization of AAV-2 infection. J. Virol. 74, 9281-93 (2000). Limited Use Label License: Research Use Only Product is exclusively licensed to PROGEN Biotechnik GmbH. The use of these products for the development, manufacturing and sale of secondary products/derivatives which are based on the purchased products and/or which include the purchased product require a royalty based sub-license agreement.

packgene.com

Showcasing scientific publications and research that utilize our high-quality services and products. See how our products are trusted by and contributing to the global research community.

nanostherapeutics.com

Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.